Stains & CD markers
Pan-TRK (EPR17341) [NTRK]

Editorial Board Member: Jose G. Mantilla, M.D.
Editor-in-Chief: Debra L. Zynger, M.D.
Benjamin F. Smith, M.D., M.S.
Jessica L. Davis, M.D.

Last author update: 1 September 2021
Last staff update: 12 August 2022

Copyright: 2003-2024,, Inc.

PubMed Search: Pan-TRK stain

Benjamin F. Smith, M.D., M.S.
Jessica L. Davis, M.D.
Page views in 2023: 7,917
Page views in 2024 to date: 3,180
Cite this page: Smith B, Davis JL. Pan-TRK (EPR17341) [NTRK]. website. Accessed May 19th, 2024.
Definition / general
  • Family of receptor tyrosine kinases (NTRK1/2/3 genes with encode Trk-A, Trk-B, Trk-C protein kinases)
  • Pan-TRK antibody recognizes C terminal domain of Trk-A, Trk-B and Trk-C (also available are Trk-A and Trk-C antibodies)
  • 2 clones, EPR17341 and A7H6R, with concordance in NTRK rearranged tumors
  • Neurotrophin signaling through these receptor kinases activate cellular pathways involved in cellular proliferation and survival, particularly within the embryonic nervous system (Annu Rev Biochem 2003;72:609, Annu Rev Neurosci 2001;24:677)
  • Within embryonal development, regulate neuronal differentiation, axonal growth, dendritic growth and pruning and membrane trafficking, among other functions (Annu Rev Biochem 2003;72:609, Annu Rev Neurosci 2001;24:677)
  • In adults, involved in synaptic strength and plasticity (Annu Rev Biochem 2003;72:609, Annu Rev Neurosci 2001;24:677)
Essential features
  • Pan-TRK antibody recognizing C terminal domain of the Trk-A, Trk-B and Trk-C proteins encoded by the NTRK1/2/3 genes
  • Can help identify tumors harboring NTRK1/2/3 fusions
  • Variable expression pattern, depending on which NTRK gene is involved
  • Variable sensitivity, depending on which NTRK gene is involved with lower sensitivity in NTRK3 gene fusions
  • NTRK gene fusions (NTRK1/2/3) to a variety of gene partners are oncogenic drivers in several tumor types
  • Recognition of NTRK fusion tumors is important with the advent of targeted Trk inhibitors
Diagrams / tables

Images hosted on other servers:

Proposed testing algorithm

Clinical features
  • Tumors with NTRK fusions are eligible for the FDA approved targeted TRK inhibitors larotrectinib and entrectinib
  • Tumors harboring NTRK1/2 fusions demonstrate cytoplasmic expression; rare perinuclear and nuclear membrane staining has been reported
  • Tumors harboring NTRK3 fusions demonstrate cytoplasmic or nuclear expression
  • Some authors consider positive staining to be if ≥ 1% of tumor cells show expression, particularly for nuclear expression in NTRK3 fusions which may show only sparse staining (Mod Pathol 2020;33:38)
  • Interpretation is best made in the context of morphology; false positive staining has rarely been reported in tumors in the absence of NTRK fusions, including BCOR rearranged sarcomas / primitive myxoid mesenchymal tumors of infancy (PMMTI), fibrous hamartoma of infancy (primitive mesenchymal component), neuroblastoma, oligodendroglioma, carcinomas with neuroendocrine differentiation, invasive ductal carcinoma of the breast and adenoid cystic carcinoma, among others; some of these tumors harbor structural rearrangements or amplifications in NTRK1-3 without gene fusions (Histopathology 2018;73:634, Mod Pathol 2020;33:38)
Uses by pathologists
Prognostic factors
  • Minimal prognostic information available; however, pan-Trk immunohistochemistry can be used as a screening tool and potential predictive marker
Microscopic (histologic) images

Contributed by Jessica L. Davis, M.D.

Infantile fibrosarcoma

Infantile fibrosarcoma spectrum of tumors

Secretory carcinoma

Positive staining - normal
Positive staining - disease
Negative staining
Molecular / cytogenetics description
  • Fluorescence in situ hybridization (FISH) probes for NTRK genes (or ETV6 which frequently is the fusion partner to NTRK3) are commercially available
  • Some NGS assays (DNA or RNA) can detect / confirm NTRK fusions
Molecular / cytogenetics images

Images hosted on other servers:
Missing Image


Board review style question #1

A 2 month old boy presents with a large intramuscular thigh mass with encasement of the femoral neurovascular bundle. Biopsy shows a spindle cell neoplasm with infiltrative borders into skeletal muscle and subcutaneous adipose tissue. By immunohistochemistry, the tumor shows patchy expression of SMA, rare CD34 and diffuse expression of pan-TRK. What is the most likely diagnosis?

  1. Cellular congenital mesoblastic nephroma
  2. Infantile fibrosarcoma
  3. Lipofibromatosis
  4. Myofibroma
Board review style answer #1
B. Infantile fibrosarcoma. Infantile fibrosarcoma is the most common soft tissue sarcoma of infancy. The morphology can be variable but typically presents with primitive to spindle cells in a myxoid to collagenized stroma; the diagnosis can be confirmed with pan-TRK antibody staining. Tumors harbor an ETV6::NTRK3 fusion in ~70% of cases; however, recently other variant NTRK fusions have been described (Pediatr Dev Pathol 2018;21:68, Mod Pathol 2018;31:463).

Comment Here

Reference: Pan-TRK (EPR17341) [NTRK]
Board review style question #2
    A 20 year old woman presents with a breast mass and a needle core biopsy is performed demonstrating morphology suggestive of secretory carcinoma. Which stain combination would be most consistent with secretory breast carcinoma?

  1. Pan-TRK+, S100+, MUC4+, ER-, GATA3+
  2. Pan-TRK+, S100-, MUC4+, ER+, GATA3+
  3. Pan-TRK-, S100-, MUC4+, ER+, GATA3+
  4. Pan-TRK+, S100+, MUC4+, ER+, GATA3+
Board review style answer #2
A. Pan-TRK+, S100+, MUC4+, ER-, GATA3+. Secretory carcinomas of the breast, salivary gland and skin are most commonly ETV6::NTRK3 driven tumors; rare ETV6 to other fusion partners have been described (Am J Surg Pathol 2015;39:602). Pan-TRK staining is seen, often with nuclear expression (NTRK3 fusion tumors). Breast secretory carcinomas also express S100, SOX10, MUC4 and GATA3 but are triple negative (ER / PR / HER2-).

Comment Here

Reference: Pan-TRK (EPR17341) [NTRK]
Back to top
Image 01 Image 02